This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sunesis Pharmaceuticals Announces Management Promotions

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced two management promotions, effective October 1, 2012. Deborah A. Thomas, Ph.D., has been promoted to Vice President, Regulatory Affairs and Gene C. Jamieson has been promoted to Vice President, Chemistry, Manufacturing and Controls (CMC).

Sunesis Pharmaceuticals, Inc. Logo

Adam Craig, M.D., Ph.D., M.B.A., Executive Vice President, Development and Chief Medical Officer of Sunesis, commented, "Debbie and Gene have been integral members of Sunesis' management team, each contributing to the rigorous and successful conduct of our Phase 3 VALOR trial of vosaroxin in acute myeloid leukemia. As we look to full enrollment of VALOR in 2013, and anticipated unblinding of the trial in the first half of 2014, Regulatory Affairs and CMC will be critical components of our commercialization efforts.  I congratulate Debbie and Gene on their well-deserved promotions, and look forward to their valued insights and leadership during this exciting time."

Dr. Thomas joined Sunesis in November 2011 as Executive Director, Regulatory Affairs. She has over 20 years of biotechnology and pharmaceutical industry experience, with broad-based expertise in toxicology, project leadership and regulatory affairs. Dr. Thomas came to Sunesis from BiPar Sciences, where she was Vice President, Regulatory Affairs, providing strategic input into their clinical development plans and serving as that company's primary point of contact to the FDA. Prior to BiPar, Dr. Thomas served in various management positions at Genentech, Inc. from 1990 to 2007, most recently as Senior Director, Department of Clinical Regulatory Affairs. Dr. Thomas was awarded a B.S. in Microbiology and Ph.D. in toxicology from the University of Kentucky.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs